Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Ekaterina Gibiansky"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 914-927 (2021)
Abstract A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (Ctrough), ensuring similar target saturation and comparable efficacy/s
Externí odkaz:
https://doaj.org/article/96de8a1a1020405cb52160c9fa76dd90
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 914-927 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
A subcutaneous formulation of the anti-CD20 antibody rituximab has been developed. Fixed-dose subcutaneous rituximab delivers non-inferior serum trough concentrations (Ctrough ), ensuring similar target saturation and comparable efficacy/safety to in
Autor:
Artem Zharkov, Axel Boehnke, Christine McIntyre, Peter N. Morcos, Linda Lundberg, Ekaterina Gibiansky, Martin Barrett, Clarisse Chavanne, Nicolas Frey, Candice Jamois, Leonid Gibiansky
Publikováno v:
Clinical Pharmacology and Therapeutics
A fixed-dose subcutaneous (s.c.) formulation of the anti-CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.v.) dosing, and has been approved based upon a pharmacokin
Autor:
Fabian Model, Ludwig Kappos, Stephen L. Hauser, Heidemarie Kletzl, Ekaterina Gibiansky, Andreas Günther, Claire Petry, Ann Herman, Francois Mercier, Yumi Yamamoto, Qing Wang
Publikováno v:
British Journal of Clinical Pharmacology
British journal of clinical pharmacology, vol 87, iss 6
British journal of clinical pharmacology, vol 87, iss 6
AimsOcrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The pharma
Autor:
Günter Fingerle-Rowson, Ekaterina Gibiansky, Michael Brewster, Vincent Buchheit, Candice Jamois, Nicolas Frey, Leonid Gibiansky
Publikováno v:
British Journal of Clinical Pharmacology
Aims Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a n
Publikováno v:
Antimicrobial Agents and Chemotherapy
A population pharmacokinetic (PopPK) model of delamanid in patients with pulmonary multidrug-resistant tuberculosis (MDR-TB) was developed using data from four delamanid clinical trials. The final PopPK data set contained 20,483 plasma samples from 7
Publikováno v:
Blood. 138:4221-4221
Background: Romiplostim, a subcutaneous treatment for adult ITP, uses a platelet response-guided dose adjustment algorithm (USPI dosing, Table 1) to maintain patients' platelet count (PC). Romiplostim was recently approved for patients with ITP ≤ 1
Autor:
Ekaterina Gibiansky, Leonid Gibiansky
Publikováno v:
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases ISBN: 9781119289234
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::888b5ffa8bb408674d5644adaf869957
https://doi.org/10.1002/9781119289234.ch8
https://doi.org/10.1002/9781119289234.ch8
Autor:
Ekaterina Gibiansky, Leonid Gibiansky
Publikováno v:
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases ISBN: 9781119289234
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74731c14195a60ec7b17c837b23a87b2
https://doi.org/10.1002/9781119289234.ch7
https://doi.org/10.1002/9781119289234.ch7
Autor:
Ekaterina Gibiansky, Leonid Gibiansky
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 45(1)
The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological